0
0
Las Vegas, October 23, 2025 — In a surprising twist that could reshape the future of epilepsy treatment, researchers at the University of Nevada, Las Vegas (UNLV) have developed a new class of cannabidiol (CBD)-like compounds not from cannabis, but from the humble caraway seed — a kitchen staple long used in traditional remedies. Early preclinical findings suggest these synthetic compounds may reduce seizures more effectively than existing therapies while fostering brain cell development without the sedative side effects many current drugs produce.
The peer-reviewed study, published in Neuropsychopharmacology in September 2025, marks a significant departure from conventional CBD research. For decades, scientists have focused on compounds extracted from cannabis plants, primarily because only one such product — Epidiolex — is currently approved by the U.S. Food and Drug Administration (FDA) for specific forms of childhood epilepsy.
Dustin Hines, Ph.D., a professor of neuroscience at UNLV and co-author of the study, said the discovery arose from a bold idea: to engineer a safer, plant-based scaffold that mimics the beneficial neurochemical actions of CBD, without relying on cannabis. “Childhood seizure disorders are often resistant to available drugs, and both the seizures and the current frontline therapies can severely affect brain development, cognition, and quality of life,” Hines explained. “Our goal was to find alternative compounds that preserve CBD’s therapeutic promise while minimizing adverse effects.”
From Spice Rack to Science Lab
The research team began with Carum carvi — the common caraway seed — and used a genetic modification technique to induce the plant to produce compounds structurally analogous to non‑intoxicating CBD molecules. These caraway-derived analogs were then isolated and tested in both adult and developmental models of epilepsy.
The results were striking. Mice treated with the new compounds experienced fewer seizures, reduced seizure-related mortality, and improved neuronal health compared to those receiving traditional anti-epileptic drugs. The findings suggest that these synthetic molecules not only suppress electrical hyperactivity in the brain but also promote neurogenesis — the growth of new brain cells, a process critical to cognitive recovery.
According to the published data, animals given the highest tolerated dose showed a 45% reduction in seizure frequency and a 60% lower seizure-related death rate than untreated controls. “This dual activity — neuroprotective and anti-seizure — is rare among existing therapies,” said Hines.
A New Therapeutic Frontier
The National Institutes of Health (NIH), through the National Institute of General Medical Sciences and the National Institute of Neurological Disorders and Stroke, funded the UNLV project. NIH officials have prioritized novel, non-opioid, and non-sedative neuroscience research initiatives given the limitations of current antiepileptic drugs.
Epilepsy affects approximately 50 million people worldwide, according to the World Health Organization (WHO), making it one of the most common neurological disorders globally. About one-third of patients have “refractory epilepsy” — seizures that fail to respond to standard medication. For these individuals, new treatment avenues are critical.
Adriana Carrillo, a UNLV undergraduate student and co-author on the paper, described the work as “both scientifically and personally rewarding.” She added, “Advancing this new class of therapeutics holds significant promise for patients who have exhausted existing treatment options, whether due to debilitating side effects or a lack of response to current therapies.”
Carrillo also cautioned that the findings should not prompt consumers to turn to caraway supplements or home remedies. “The compounds we studied are synthesized from the molecular structure of caraway, but consuming the seeds themselves won’t yield therapeutic effects,” she noted. “It’s the result of precise laboratory modification and purification.”
Expert Perspectives
Dr. Anupam Mahajan, a neurologist at the Cleveland Clinic not involved in the research, commended the work for “expanding the chemical diversity in CNS drug discovery.” He emphasized, however, that safety and reproducibility are paramount before moving to human trials. “CBD analogs have shown great promise in preclinical animal studies before, but translating those benefits reliably to people — especially children — requires rigorous testing of pharmacokinetics, purity, and potential drug interactions,” Mahajan told Healthline Science Review.
Dr. Sarah Ellison, a pharmacologist at the University of Toronto specializing in cannabinoid signaling, described the research as an “elegant example of bio‑inspired design.” She noted that leveraging plant scaffolds outside cannabis could yield “new neurotherapeutic compounds with fewer regulatory barriers and potentially improved tolerability.”
Context: The Challenge of Epilepsy Treatment
Existing antiepileptic drugs (AEDs) can help control seizures in most patients, but many come with cognitive side effects such as memory impairment, fatigue, and drowsiness. In children, chronic use of certain AEDs has been linked to slower developmental milestones. While cannabis-derived CBD has improved outcomes for patients with treatment-resistant Dravet and Lennox-Gastaut syndromes, its mechanism remains incompletely understood, and not all patients benefit.
The UNLV team hopes that caraway-derived CBD analogs could offer a novel pharmacological route — one that combines the efficacy of CBD with easier regulation and potentially broader therapeutic applications.
Limitations and Next Steps
Researchers caution that these results, while encouraging, are still in early stages. All findings so far are based on animal models. The next steps involve confirming safety, dosing, and effectiveness in larger preclinical studies before moving toward first-in-human trials.
Bioavailability — how efficiently a drug is absorbed and reaches the brain — remains another major focus. Previous synthetic cannabinoids have failed in clinical trials because they degraded quickly or triggered unintended immune responses. “Our next challenge is to ensure stability and efficient brain delivery,” Hines said.
Public Health Implications
If successful, this line of research could transform treatment for patients with refractory epilepsy and potentially other neurological conditions involving dysfunctional neuronal signaling, such as traumatic brain injury or Alzheimer’s disease. Because the compounds are derived from a non‑cannabis plant, they may also sidestep stigma or regulatory hurdles that sometimes complicate cannabinoid research.
Still, experts urge cautious optimism. “Drug development is a marathon, not a sprint,” said Mahajan. “But the idea of repurposing everyday botanical compounds to generate next-generation epilepsy therapeutics is undeniably exciting.”
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Hines, D. J., Carrillo, A., et al. (2025). Caraway-derived cannabidiol analogs suppress seizures and promote neurogenesis in rodent models of epilepsy. Neuropsychopharmacology. doi:10.1038/npp.2025.142
